BMBIF BRIGHT MINDS BIOSCIENCES

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$6.71    OTCQB
As of 10/22/2021     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Unknown
Industry:  
Index country:  Canada
Country of incorporation:  
IPO date:  08/09/2021
Outstanding shares:  11,834,361
Average volume:  13,780
Market cap:   $80,260,636
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.96
PS ratio:   0.00
Return on equity:   -26.81%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy